Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Women With PCOS Undergoing PGT-A

Launched by SHANGHAI JI AI GENETICS & IVF INSTITUTE · Apr 9, 2022

Keywords

ClinConnect Summary

This clinical trial is studying two different methods of stimulating the ovaries in women with polycystic ovary syndrome (PCOS) who are undergoing a procedure called preimplantation genetic testing for aneuploidy (PGT-A). The goal is to see which method, progestin-primed ovarian stimulation (PPOS) or a GnRH antagonist protocol, results in a higher number of healthy embryos, known as euploid blastocysts. Women aged 20 to 37 years with a diagnosis of PCOS may be eligible to participate.

If you join the trial, you will be randomly assigned to one of two groups. One group will receive daily injections to help stimulate the ovaries, while the other will take a daily oral medication for the same purpose. The trial is not yet recruiting participants, but if you qualify, you will have the opportunity to contribute to important research that could help improve fertility treatments for women with PCOS. It's essential to note that only women with specific health conditions can participate, and certain factors, like having previous unsuccessful embryo transfers or specific uterine abnormalities, may exclude you from the study.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Women age between 20 and 37 years.
• • Women diagnosed with PCOS according to the modified Rotterdam criteria: oligomenorrhea or amenorrhea, together with the presence of ≥12 antral follicles (≤9 mm) and/or ovarian volume \>10 mL on transvaginal ultrasonographic scanning, and/or clinical/ biochemical hyperandrogenism. Other causes of hyperandrogenism and ovulation dysfunction-including tumours, congenital adrenal hyperplasia, hyperprolactinaemia and thyroid dysfunction-were excluded
• Exclusion Criteria:
• • Presence of a functional ovarian cyst with E2\>100 pg/mL
• • Endometriosis grade 3 or higher
• • Repeated implantation failure (\>=4 embryos replaced or \>=2 blastocysts replaced without success)
• • Women with a uterine cavity abnormality, such as a uterine congenital malformation (uterus uni-cornate, bicornate, or duplex); untreated uterine septum, adenomyosis, submucous myoma, or endo-metrial polyp(s)
• • Women who are indicated and planned to undergo PGT-SR (Preimplantation genetic testing for structural rearrangement) or PGT-M (Preimplantation genetic testing for monogenic disorder), for example, parental abnormal karyo-type or diagnosed with monogenic disease;
• • Recipient of oocyte donation
• • Presence of hydrosalpinx which is not surgically treated